Karyopharm Therapeutics Inc (KPTI)

전일 마감가:

$1.135

열려 있는:

$1.15

하루 거래량:

1.56M

시가총액:

$135.37M

수익:

$146.03M

순이익/손실:

$-143.10M

주가수익비율:

-0.8712

EPS:

-1.32

순현금흐름:

$-92.72M

1주 성능:

+5.50%

1개월 성능:

-16.67%

6개월 성능:

+47.44%

1년 성능:

-53.06%

1일 변동 폭

$1.125

$1.19

52주 변동 폭

$0.6174

$2.67

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

명칭

Karyopharm Therapeutics Inc

부문

Healthcare (1209)

산업

Biotechnology (699)

전화

617-658-0600

주소

85 Wells Avenue, 2nd Floor, Newton, MA

직원

154

트위터

@Karyopharm

다음 수익 날짜

2024-05-29

최신 SEC 제출 서류

KPTI's Discussions on Twitter

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-01-19	개시	Piper Sandler	Overweight
2022-11-04	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2022-02-09	업그레이드	JP Morgan	Underweight → Neutral
2021-11-19	재개	Morgan Stanley	Equal-Weight
2021-08-06	다운그레이드	JP Morgan	Overweight → Neutral
2021-08-06	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2021-08-06	다운그레이드	SVB Leerink	Outperform → Mkt Perform
2020-07-02	개시	Morgan Stanley	Overweight
2020-03-04	개시	Barclays	Overweight
2020-01-17	다운그레이드	Wedbush	Outperform → Neutral
2019-07-23	업그레이드	JP Morgan	Neutral → Overweight
2019-07-05	재확인	H.C. Wainwright	Buy
2019-07-05	재확인	Robert W. Baird	Outperform
2019-03-01	다운그레이드	JP Morgan	Overweight → Neutral
2019-02-28	재확인	BofA/Merrill	Underperform
2019-02-27	다운그레이드	BofA/Merrill	Neutral → Underperform
2019-01-03	업그레이드	BofA/Merrill	Underperform → Neutral
2018-12-03	개시	B. Riley FBR	Buy
2018-11-09	업그레이드	Wedbush	Neutral → Outperform
2018-05-24	다운그레이드	Wedbush	Outperform → Neutral
2018-04-02	재개	Leerink Partners	Outperform
2017-11-15	재개	H.C. Wainwright	Buy
2017-09-15	개시	RBC Capital Mkts	Outperform
2016-09-08	재확인	H.C. Wainwright	Buy
2016-08-30	업그레이드	Jefferies	Hold → Buy
2016-08-18	개시	H.C. Wainwright	Buy
2016-06-28	개시	Robert W. Baird	Outperform

모두보기

Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스

Selling Buzz: Karyopharm Therapeutics Inc [KPTI] President and CEO Paulson Richard A. sells 3576 shares of the ... - Knox Daily

Knox Daily

UPDATE 2-Karyopharm Therapeutics prices blood cancer treatment after FDA approval - Yahoo Sport Australia

Yahoo Sport Australia

Karyopharm's Refinancing Transactions and Amended Royalty Agreement – Global Legal Chronicle - Global Legal Chronicle

Global Legal Chronicle

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Moderate Buy" from ... - MarketBeat

MarketBeat

JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - GlobeNewswire

GlobeNewswire

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Defense World

Karyopharm Therapeutics Inc (KPTI) 재무 분석

Karyopharm Therapeutics Inc (KPTI) 매출 2024

Karyopharm Therapeutics Inc (KPTI) 순이익 2024

Karyopharm Therapeutics Inc (KPTI) 현금흐름 2024

Karyopharm Therapeutics Inc (KPTI) 주당 순이익 2024